| Li, Xiang |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
NCT03989336: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
|
|
| Completed | 2 | 84 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Platinum chemotherapy, Sintilimab, anti-PD-1 antibody; PD-1 inhibitor | Chinese PLA General Hospital | Ovarian Cancer | 05/22 | 12/23 | | |
NCT03250962: SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 280 | RoW | SHR-1210, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 07/22 | 03/25 | | |
NCT04514081: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. |
|
|
| Recruiting | 2 | 200 | RoW | Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab | Chinese PLA General Hospital | Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant | 08/22 | 08/25 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Not yet recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
CHN-PLAGH-BT-045, NCT04233294: Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 100 | RoW | Chidamide, Camrelizumab, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 02/24 | 02/26 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT03989310: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 50 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Gemcitabine, anti-PD-1 antibody, Anti-PD-1 monoclonal antibody; PD-1 inhibitor | Chinese PLA General Hospital | Pancreatic Cancer | 05/21 | 03/22 | | |
NCT06232863: A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer |
|
|
| Recruiting | 1 | 24 | RoW | BH009 | Zhuhai Beihai Biotech Co., Ltd | Solid Tumor, Adult | 03/24 | 04/24 | | |
NCT05190861: Evaluation of Droplet Digital PCR Rapid Detection Method and Precise Diagnosis and Treatment for Suspected Sepsis |
|
|
| Recruiting | N/A | 2000 | RoW | droplet digital PCR method, blood culture | Huashan Hospital | Sepsis, Septic Shock | 12/22 | 06/23 | | |
NCT06212934: "Chou's Tiaoshen" Acupoints for Short-term Insomnia. |
|
|
| Not yet recruiting | N/A | 96 | RoW | Acupuncture, Dry needle, Estazolam, Estazolam pill | Beijing Hospital of Traditional Chinese Medicine | Short-term Insomnia | 03/25 | 05/25 | | |
NCT06394089: Effect of Degenerative Spondylolisthesis on the Clinical Outcome of Unilateral Biportal Endoscopy for Lumbar Spinal Stenosis: Study Protocol |
|
|
| Recruiting | N/A | 150 | RoW | | Beijing Friendship Hospital | Degenerative Spondylolisthesis, Lumbar Spinal Stenosis | 02/27 | 02/27 | | |
ESAR, NCT04955756: Early Identification and Severity Prediction of Acute Respiratory Infectious Disease |
|
|
| Recruiting | N/A | 440 | RoW | mNGS, Multiplex PCR | Huashan Hospital | Acute Respiratory Infection, Severe Pneumonia, Next Generation Sequencing, Multiplex PCR | 12/24 | 12/24 | | |
